Melanoma - Pipeline Review, H2 2016

Date: December 28, 2016
Pages: 1656
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until March 3, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M94D1D30D60EN
Leaflet:

Download PDF Leaflet

Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma – Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Melanoma Overview
Therapeutics Development
Melanoma - Therapeutics under Development by Companies
Melanoma - Therapeutics under Investigation by Universities/Institutes
Melanoma - Pipeline Products Glance
Melanoma - Products under Development by Companies
Melanoma - Products under Investigation by Universities/Institutes
Melanoma - Companies Involved in Therapeutics Development
Melanoma - Therapeutics Assessment
Drug Profiles
Melanoma - Dormant Projects 1537
Melanoma - Discontinued Products 1580
Melanoma - Product Development Milestones 1585
Appendix 1598

LIST OF TABLES

Number of Products under Development for Melanoma, H2 2016
Number of Products under Development for Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016 (Contd..19)
Number of Products under Development by Companies, H2 2016 (Contd..20)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Melanoma - Pipeline by 4SC AG, H2 2016
Melanoma - Pipeline by AB Science SA, H2 2016
Melanoma - Pipeline by AbbVie Inc, H2 2016
Melanoma - Pipeline by Abivax SA, H2 2016
Melanoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Melanoma - Pipeline by Adicet Bio Inc, H2 2016
Melanoma - Pipeline by Aduro BioTech Inc, H2 2016
Melanoma - Pipeline by Advanced Cancer Therapeutics, H2 2016
Melanoma - Pipeline by Advaxis Inc, H2 2016
Melanoma - Pipeline by Aeterna Zentaris Inc, H2 2016
Melanoma - Pipeline by Affichem SA, H2 2016
Melanoma - Pipeline by Agalimmune Ltd, H2 2016
Melanoma - Pipeline by Agenus Inc, H2 2016
Melanoma - Pipeline by Agilvax Inc, H2 2016
Melanoma - Pipeline by AGV Discovery SAS, H2 2016
Melanoma - Pipeline by AIMM Therapeutics BV, H2 2016
Melanoma - Pipeline by Alethia Biotherapeutics Inc, H2 2016
Melanoma - Pipeline by Altor BioScience Corp, H2 2016
Melanoma - Pipeline by Amgen Inc, H2 2016
Melanoma - Pipeline by Anavex Life Sciences Corp, H2 2016
Melanoma - Pipeline by Angimmune LLC, H2 2016
Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2016
Melanoma - Pipeline by Antigen Express Inc, H2 2016
Melanoma - Pipeline by APEIRON Biologics AG, H2 2016
Melanoma - Pipeline by Apexigen Inc, H2 2016
Melanoma - Pipeline by Aphios Corp, H2 2016
Melanoma - Pipeline by APO-T BV, H2 2016
Melanoma - Pipeline by Apogenix GmbH, H2 2016
Melanoma - Pipeline by Aposense Ltd, H2 2016
Melanoma - Pipeline by Aptose Biosciences Inc, H2 2016
Melanoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by ARMO Biosciences Inc, H2 2016
Melanoma - Pipeline by Array BioPharma Inc, H2 2016
Melanoma - Pipeline by Asana BioSciences LLC, H2 2016
Melanoma - Pipeline by Astellas Pharma Inc, H2 2016
Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by AstraZeneca Plc, H2 2016
Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Melanoma - Pipeline by Azaya Therapeutics Inc, H2 2016
Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
Melanoma - Pipeline by Batu Biologics Inc, H2 2016
Melanoma - Pipeline by Bayer AG, H2 2016
Melanoma - Pipeline by BeiGene Ltd, H2 2016
Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016
Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by BerGenBio AS, H2 2016
Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
Melanoma - Pipeline by Biocad, H2 2016
Melanoma - Pipeline by Biogazelle NV, H2 2016
Melanoma - Pipeline by Biogenomics Ltd, H2 2016
Melanoma - Pipeline by BioLineRx Ltd, H2 2016
Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016
Melanoma - Pipeline by Bionomics Ltd, H2 2016
Melanoma - Pipeline by BioNTech AG, H2 2016
Melanoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016
Melanoma - Pipeline by Biovista Inc, H2 2016
Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Melanoma - Pipeline by Boston Biomedical Inc, H2 2016
Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Melanoma - Pipeline by Calithera Biosciences Inc, H2 2016
Melanoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2016
Melanoma - Pipeline by Cellceutix Corp, H2 2016
Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
Melanoma - Pipeline by Celprogen Inc, H2 2016
Melanoma - Pipeline by Celyad SA, H2 2016
Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by Cortice Biosciences Inc, H2 2016
Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by CytomX Therapeutics Inc, H2 2016
Melanoma - Pipeline by Cytune Pharma SAS, H2 2016
Melanoma - Pipeline by CyTuVax BV, H2 2016
Melanoma - Pipeline by CZ BioMed Corp, H2 2016
Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
Melanoma - Pipeline by DEKK-TEC Inc, H2 2016
Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
Melanoma - Pipeline by DormaTarg Inc, H2 2016
Melanoma - Pipeline by Dynavax Technologies Corp, H2 2016
Melanoma - Pipeline by Eisai Co Ltd, H2 2016
Melanoma - Pipeline by Eli Lilly and Company, H2 2016
Melanoma - Pipeline by Elsalys Biotech SAS, H2 2016
Melanoma - Pipeline by Ensol Biosciences Inc, H2 2016
Melanoma - Pipeline by EntreChem SL, H2 2016
Melanoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016
Melanoma - Pipeline by Evelo Therapeutics Inc, H2 2016
Melanoma - Pipeline by Exelixis Inc, H2 2016
Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Melanoma - Pipeline by Faes Farma SA, H2 2016
Melanoma - Pipeline by Five Prime Therapeutics Inc, H2 2016
Melanoma - Pipeline by Formune SL, H2 2016
Melanoma - Pipeline by Galapagos NV, H2 2016
Melanoma - Pipeline by Galectin Therapeutics Inc, H2 2016
Melanoma - Pipeline by Genelux Corp, H2 2016
Melanoma - Pipeline by Genocea Biosciences Inc, H2 2016
Melanoma - Pipeline by Genzyme Corp, H2 2016
Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016 241

LIST OF FIGURES

Number of Products under Development for Melanoma, H2 2016
Number of Products under Development for Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Uveal Melanoma - Pipeline Review, H2 2016 US$ 1,700.00 Sep, 2016 · 108 pages
Uveal Melanoma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 115 pages
Metastatic Uveal Melanoma - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 59 pages
Metastatic Uveal Melanoma - Pipeline Review, H2 2016 US$ 1,700.00 Dec, 2016 · 56 pages
Melanoma - Pipeline Review, 2015 US$ 3,000.00 Oct, 2015 · 86 pages

Ask Your Question

Melanoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: